LeMaitre Vascular (NASDAQ:LMAT) Earns “Outperform” Rating from Oppenheimer

Oppenheimer reaffirmed their outperform rating on shares of LeMaitre Vascular (NASDAQ:LMAT) in a research report report published on Friday, Benzinga reports. The brokerage currently has a $93.00 price objective on the medical instruments supplier’s stock, up from their prior price objective of $90.00.

Several other analysts have also recently weighed in on LMAT. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Barrington Research raised their price objective on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research note on Friday. JMP Securities lifted their price target on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 20th. Lake Street Capital initiated coverage on LeMaitre Vascular in a report on Friday, August 2nd. They issued a “buy” rating and a $105.00 price target on the stock. Finally, Cantor Fitzgerald initiated coverage on shares of LeMaitre Vascular in a report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 target price for the company. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $94.57.

LeMaitre Vascular Stock Up 1.5 %

NASDAQ:LMAT opened at $96.35 on Friday. The firm has a market cap of $2.16 billion, a PE ratio of 52.65, a price-to-earnings-growth ratio of 2.32 and a beta of 0.89. LeMaitre Vascular has a 12 month low of $47.72 and a 12 month high of $101.67. The company’s 50-day moving average price is $89.70 and its two-hundred day moving average price is $83.49.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. The firm had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.39%. The company’s revenue was up 15.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.33 EPS. On average, research analysts expect that LeMaitre Vascular will post 1.86 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 5th. Investors of record on Thursday, November 21st will be issued a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.66%. The ex-dividend date is Thursday, November 21st. LeMaitre Vascular’s payout ratio is presently 34.97%.

Insider Buying and Selling at LeMaitre Vascular

In other news, Director David B. Roberts sold 3,063 shares of the stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the transaction, the director now directly owns 14,114 shares of the company’s stock, valued at $1,158,335.98. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 10.79% of the company’s stock.

Institutional Trading of LeMaitre Vascular

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of LeMaitre Vascular by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier’s stock valued at $87,914,000 after buying an additional 38,303 shares during the period. Norden Group LLC bought a new position in LeMaitre Vascular during the 1st quarter worth approximately $401,000. BNP Paribas Financial Markets lifted its holdings in LeMaitre Vascular by 135.6% in the first quarter. BNP Paribas Financial Markets now owns 22,917 shares of the medical instruments supplier’s stock valued at $1,521,000 after buying an additional 13,189 shares during the period. Whitegate Investment Counselors Inc. acquired a new position in shares of LeMaitre Vascular in the 1st quarter valued at about $216,000. Finally, Texas Permanent School Fund Corp lifted its stake in LeMaitre Vascular by 1.3% in the first quarter. Texas Permanent School Fund Corp now owns 17,341 shares of the medical instruments supplier’s stock valued at $1,151,000 after buying an additional 225 shares during the period. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.